A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

NCT06310304 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: Ruxolitinib IR
DRUG: Ruxolitinib XR

Sponsor

Incyte Corporation